Eli Lilly's Mounjaro has overtaken Keytruda to become the world's top-selling medicine. Its rise highlights booming demand ...

Mounjaro generated $8.7 billion for Lilly in the first quarter of 2026, outperforming Merck's Keytruda, which posted sales of ...

Eli Lilly & Co.’s blockbuster diabetes drug Mounjaro has surpassed Merck & Co.’s cancer therapy Keytruda as the world’s ...

Samsung Bioepis announces positive preliminary Phase 1 data for SB27, proposed biosimilar to keytruda (Pembrolizumab).

Agilent Technologies (A) is back in focus after receiving U.S. FDA approval for its PD-L1 IHC 22C3 pharmDx assay as a ...

The Gibraltar Health Authority has begun using the subcutaneous form of Pembrolizumab for the treatment of some cancers, with ...

Merck (NYSE:MRK | MRK Price Prediction) delivered its fourth consecutive earnings beat, but shares slipped on the earnings ...

Merck narrowed its 2026 sales guidance and hiked its adjusted profit outlook.

Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities ...

By Deena Beasley and Mariam Sunny April 30 (Reuters) - Merck on Thursday beat first-quarter sales expectations on strong ...

Merck reported higher first-quarter sales and raised its full-year earnings guidance as demand for its flagship Keytruda ...